Opexa Therapeutics Inc. (NASDAQ:OPXA) received a $18.00 target price from research analysts at Maxim Group in a report released on Tuesday. The brokerage currently has a a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price target would suggest a potential upside of 423.26% from the stock’s previous close.

Several other analysts also recently commented on OPXA. Chardan Capital reaffirmed a “buy” rating and set a $6.00 price objective on shares of Opexa Therapeutics in a research report on Sunday, July 3rd. Aegis raised their price objective on shares of Opexa Therapeutics to $11.00 and gave the stock a “buy” rating in a research report on Monday, July 18th. Finally, Zacks Investment Research cut Opexa Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 20th.

Opexa Therapeutics (NASDAQ:OPXA) traded down 6.6831% during trading on Tuesday, hitting $3.2101. 96,448 shares of the company’s stock traded hands. The company’s 50 day moving average price is $4.12 and its 200 day moving average price is $3.28. Opexa Therapeutics has a 52-week low of $1.69 and a 52-week high of $5.10. The company’s market cap is $22.63 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/opexa-therapeutics-inc-opxa-given-a-18-00-price-target-at-maxim-group.html

Opexa Therapeutics (NASDAQ:OPXA) last announced its quarterly earnings data on Thursday, August 11th. The biopharmaceutical company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.07. Opexa Therapeutics had a negative return on equity of 109.48% and a negative net margin of 324.97%. During the same quarter last year, the company posted ($0.56) EPS. Analysts expect that Opexa Therapeutics will post ($1.12) earnings per share for the current year.

A hedge fund recently raised its stake in Opexa Therapeutics stock. Vanguard Group Inc. boosted its position in Opexa Therapeutics Inc. (NASDAQ:OPXA) by 5.6% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 164,354 shares of the biopharmaceutical company’s stock after buying an additional 8,649 shares during the period. Vanguard Group Inc. owned 2.35% of Opexa Therapeutics worth $679,000 as of its most recent filing with the SEC. Institutional investors own 6.40% of the company’s stock.

About Opexa Therapeutics

Opexa Therapeutics, Inc (Opexa) is a biopharmaceutical company. The Company is engaged in the development of a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on its T-cell technology.

5 Day Chart for NASDAQ:OPXA

Receive News & Ratings for Opexa Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opexa Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.